iBio (IBIO) Total Liabilities (2011 - 2026)

iBio (IBIO) has reported Total Liabilities for 16 consecutive years, with $13.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Liabilities rose 61.31% year-over-year to $13.4 million in Q2 2026; TTM through Jun 2026 was $13.4 million, a 61.31% increase from a year earlier, with the FY2026 full-year figure at $13.4 million, up 61.31% from the prior year.
• Total Liabilities was $13.4 million for Q2 2026 at iBio, up from $8.3 million in the prior quarter.
• Over five years, Total Liabilities peaked at $36.2 million in Q3 2022 and troughed at $6.8 million in Q3 2024.
• A 5-year average of $19.1 million and a median of $18.9 million in 2023 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities plunged 72.36% in 2024 and surged 61.31% in 2026, its largest moves.
• Over 5 years, Total Liabilities stood at $33.0 million in 2022, then slipped by 24.72% to $24.8 million in 2023, then slumped by 68.57% to $7.8 million in 2024, then gained by 0.4% to $7.8 million in 2025, then jumped by 71.03% to $13.4 million in 2026.
• The last three Total Liabilities figures came in at $13.4 million (Q2 2026), $8.3 million (Q1 2026), and $7.8 million (Q4 2025), per Business Quant data.